| scholarly article | Q13442814 |
| P2093 | author name string | Turck D | |
| Ategbo S | |||
| Druon D | |||
| Launay V | |||
| Loeuille GA | |||
| Vic P | |||
| Deschildre A | |||
| Sardet A | |||
| Husson MO | |||
| Arrouet-Lagande C | |||
| P2860 | cites work | Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection | Q34056063 |
| Single daily dose therapy with aminoglycosides | Q36517464 | ||
| Pharmacokinetic evaluation of single daily dose amikacin | Q37193898 | ||
| Once-daily aminoglycoside therapy | Q37730823 | ||
| Once-daily aminoglycoside administration: new strategies for an old drug | Q38239743 | ||
| Endobronchial infection in cystic fibrosis. | Q38790989 | ||
| Strategies and perspectives in treatment of respiratory infections | Q38791006 | ||
| Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal | Q39820716 | ||
| Antibiotic therapy in cystic fibrosis: evaluation of clinical trials | Q40808575 | ||
| Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations | Q40918381 | ||
| Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man | Q43467285 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Once daily dosing of aminoglycoside: one step forward | Q67920889 | ||
| Home intravenous antibiotic treatment of patients with cystic fibrosis | Q68157478 | ||
| Cystic fibrosis | Q68928724 | ||
| Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study | Q70363398 | ||
| Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients | Q71338545 | ||
| Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients | Q71765938 | ||
| Home care in cystic fibrosis patients | Q72221708 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 536-539 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | Archives of Disease in Childhood | Q4787296 |
| P1476 | title | Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. | |
| P478 | volume | 78 |
| Q43691124 | Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia |
| Q35043373 | Clinical issues surrounding once-daily aminoglycoside dosing in children |
| Q37333080 | Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis |
| Q24202855 | Duration of intravenous antibiotic therapy in people with cystic fibrosis |
| Q24234667 | Duration of intravenous antibiotic therapy in people with cystic fibrosis |
| Q24243031 | Duration of intravenous antibiotic therapy in people with cystic fibrosis |
| Q38943109 | Duration of intravenous antibiotic therapy in people with cystic fibrosis. |
| Q44041308 | Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. |
| Q44462274 | Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis |
| Q36191093 | Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis |
| Q36997685 | Extended-Interval Aminoglycoside Use in Cystic Fibrosis Exacerbation in Children and Young Adults: A Prospective Quality Improvement Project |
| Q37661512 | Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis |
| Q37909115 | Improved outcomes of patients with end-stage cystic fibrosis requiring invasive mechanical ventilation for acute respiratory failure |
| Q24188313 | Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis |
| Q35060166 | Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? |
| Q44999792 | Management of pulmonary involvement in mucoviscidosis in the child |
| Q36063806 | National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations |
| Q38051316 | Once daily dosing of aminoglycosides in pediatric cystic fibrosis patients: a review of the literature |
| Q45262881 | Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial |
| Q33928699 | Once-daily dosing of aminoglycoside antibiotics |
| Q43956529 | Once-daily tobramycin monotherapy in cystic fibrosis. |
| Q24200604 | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis |
| Q24203710 | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis |
| Q24241057 | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis |
| Q24245058 | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis |
| Q38871831 | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. |
| Q38133781 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. |
| Q35623060 | Pharmacodynamics and dosing of aminoglycosides |
| Q87043419 | Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis |
| Q34297656 | Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients |
| Q45019997 | Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis |
| Q33979054 | Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration |
| Q34324105 | Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. |
| Q34111815 | Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis |
| Q34358536 | Pseudomonal infection in cystic fibrosis: the battle continues |
| Q45128908 | Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis |
| Q34112917 | The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? |
| Q37115654 | Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach |
| Q43276198 | Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients |
| Q85155745 | Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis |
| Q79363107 | [Antibiotic therapy against Pseudomonas aeruginosa and other gram-negative bacteria in cystic fibrosis] |
| Q73899274 | [Antibiotic therapy in cystic fibrosis. I. Pharmacologic specifics of antibiotics] |
| Q54043285 | [Antibiotic therapy in cystic fibrosis. II Antibiotic strategy] |
| Q79363103 | [Pathogenic bacteria in cystic fibrosis] |
Search more.